Eli Lilly and Company India (Lilly) and Boehringer Ingelheim India launched HumaPen Savvio, an insulin delivery pen that meets the diabetics’ individual need. Engineered to resemble a small personal accessory rather than a medical device, this latest innovation was designed following feedback from people with diabetes who shared their aspiration to manage diabetes discreetly. An invention by Lilly, it offers an extended shelf life of up to six years after first use.
It will be co-promoted by the Lilly-Boehringer Ingelheim alliance in India. The device is designed similar to a fashionable, compact pen with durable design and will be available in a range of colours – red, graphite, green and silver. HumaPen Savvio also makes dosing easy and insulin delivery discreet, which helps insulin users feel more at ease when using their medication.
Edgard Olaizola, Managing Director, Eli Lilly and Company India said, “It will help to bring a greater sense of normalcy to using insulin. We will continue to introduce innovative products to address the unmet needs of patients amidst the growing Indian diabetes epidemic.”
Sharad Tyagi, Managing Director, Boehringer Ingelheim India said, “We are constantly working towards pioneering interventions by leveraging scientific know-how and commercial capabilities of both companies and expanding our product portfolio for diabetes in India.”
HumaPen Savvio will be available in India across six metros; Delhi, Mumbai, Kolkata, Chennai, Hyderabad and Bangalore for use with 3 mL insulin cartridges Humalog, Humalog Mix25 and Humalog Mix50 on doctor’s prescription.
EP News Bureau – Mumbai